Zobrazeno 1 - 10
of 765
pro vyhledávání: '"Albert, J"'
Autor:
Sagar A. Patel, Brian Baumann, Jeff Michalski, Randall Brenneman, Bill Zheng, Hiram Gay, Daniel Ferraro, Simon A. Brown, Albert J. Chang, Peter J. Rossi, Benjamin W. Fischer-Valuck
Publikováno v:
Brachytherapy. 22:310-316
Autor:
Lubna N. Chaudhary, Inna Chervoneva, Amy R. Peck, Yunguang Sun, Misung Yi, John F. Langenheim, Julie M. Jorns, Sailaja Kamaraju, Yee Chung Cheng, John Burfeind, Christopher R. Chitambar, Jeffrey A. Hooke, Albert J. Kovatich, Craig Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Terry Hyslop, Richard Pestell, Edith P. Mitchell, Hallgeir Rui
Publikováno v:
Cancer Research. 83:P2-11
Background PD-1 inhibitors have shown significant efficacy in triple negative breast cancer (BC), however, durable responses are less common in estrogen receptor-positive (ER+) BC. Better markers are therefore needed that will identify likely respond
Autor:
Luca F. Valle, Tommy Jiang, Adam B. Weiner, Robert E. Reiter, Matthew B. Rettig, John Shen, Albert J. Chang, Nicholas G. Nickols, Michael L. Steinberg, Amar U. Kishan
Publikováno v:
Current Oncology Reports. 25:221-229
Autor:
Jeffrey M, Jacobson, David, Zahrieh, Carrie A, Strand, Marcia, Cruz-Correa, Surakit, Pungpapong, Lewis R, Roberts, Sumithra J, Mandrekar, Luz María, Rodriguez, Jean, Boyer, Idania, Marrero, Kimberly A, Kraynyak, Matthew P, Morrow, Albert J, Sylvester, Jan M, Pawlicki, Elisabeth, Gillespie, Eduardo, Barranco, Ellen, Richmond, Asad, Umar, David B, Weiner, Paul J, Limburg
Publikováno v:
Cancer Prevention Research. 16:163-173
Chronic hepatitis C can lead to cirrhosis and hepatocellular carcinoma. We studied the safety and immunogenicity of a novel therapeutic hepatitis C virus (HCV) genotype 1a/1b consensus DNA vaccine, INO-8000, encoding HCV NS3, NS4A, NS4B, and NS5A pro
Autor:
Michael Baumann, Carol Bacchus, Marianne C. Aznar, Rob P. Coppes, Eric Deutsch, Dietmar Georg, Karin Haustermans, Peter Hoskin, Mechthild Krause, Eric F. Lartigau, Anne W.M. Lee, Steffen Löck, Birgitte V. Offersen, Jens Overgaard, David I. Thwaites, Albert J. van der Kogel, Uulke A. van der Heide, Vincenzo Valentini
Publikováno v:
Baumann, M, Bacchus, C, Aznar, M C, Coppes, R P, Deutsch, E, Georg, D, Haustermans, K, Hoskin, P, Krause, M, Lartigau, E F, Lee, A W M, Löck, S, Offersen, B V, Overgaard, J, Thwaites, D I, van der Kogel, A J, van der Heide, U A & Valentini, V 2023, ' Are hybrid conferences the new standard? ', Radiotherapy and Oncology, vol. 184, 109695 . https://doi.org/10.1016/j.radonc.2023.109695
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c181da62651abb2fdba91ae925c5a7
https://pure.au.dk/portal/da/publications/are-hybrid-conferences-the-new-standard(80af5676-da6d-43e4-b52a-d439beee6eee).html
https://pure.au.dk/portal/da/publications/are-hybrid-conferences-the-new-standard(80af5676-da6d-43e4-b52a-d439beee6eee).html
Autor:
Mark T. Corkum, Mark K. Buyyounouski, Albert J. Chang, Hans T. Chung, Peter Chung, Brett W. Cox, Juanita M. Crook, Brian J. Davis, Steven J. Frank, Ivan Henriquez, Eric M. Horwitz, Peter Hoskin, I-Chow Hsu, Mira Keyes, Martin T. King, Marisa A. Kollmeier, Daniel J. Krauss, Andrzej M. Kukielka, Gerard Morton, Peter F. Orio, Bradley R. Pieters, Louis Potters, Peter J. Rossi, Timothy N. Showalter, Abhishek A. Solanki, Daniel Song, Ben Vanneste, Eric Vigneault, Piotr A. Wojcieszek, Michael J. Zelefsky, Mitchell Kamrava
Publikováno v:
Radiotherapy and oncology, 184:109672. Elsevier Ireland Ltd
Radiotherapy and Oncology, 184:109672. Elsevier Ireland Ltd
Radiotherapy and Oncology, 184:109672. Elsevier Ireland Ltd
Background and Purpose: Local recurrences after previous radiotherapy (RT) are increasingly being identified in biochemically recurrent prostate cancer. Salvage prostate brachytherapy (BT) is an effective and well tolerated treatment option. We sough
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae21e4a6756492ceff8636cf551050d8
https://pure.amc.nl/en/publications/salvage-prostate-brachytherapy-in-radiorecurrent-prostate-cancer(10a618af-3823-438d-acb1-38b682c83559).html
https://pure.amc.nl/en/publications/salvage-prostate-brachytherapy-in-radiorecurrent-prostate-cancer(10a618af-3823-438d-acb1-38b682c83559).html
Autor:
Mariana Arevalo, Trevor A. Pickering, Sally W. Vernon, Kayo Fujimoto, Melissa F. Peskin, Albert J. Farias
Publikováno v:
Cancer Medicine. 12:1949-1960
We examined whether breast cancer survivors' experiences with care differed by a recent history of clinical depression, and whether associations differed by race/ethnicity.Using the Epidemiology and End Results-Consumer Assessment of Healthcare Provi
Autor:
Michael Xiang, Karim Chamie, Alexandra Drakaki, Amar U. Kishan, Erqi L. Pollom, Albert J. Chang, Michael L. Steinberg
Publikováno v:
Clinical Genitourinary Cancer. 20:e94-e103
Introduction : Use of hypofractionated radiation (HFRT) and intensity-modulated radiation (IMRT) for organ preservation in bladder cancer is controversial and highly variable. We investigated practice patterns, trends, and predictors of HFRT and IMRT
Autor:
Carol Y. Ochoa, Junhan Cho, Kimberly A. Miller, Lourdes Baezconde-Garbanati, Randall Y. Chan, Albert J. Farias, Joel E. Milam
Publikováno v:
Journal of Cancer Survivorship.
Purpose While limited, dyadic research demonstrates the interdependent relationship between the health and adjustment after treatment between cancer survivors and caregivers. We examined interrelationships between coping resources and mental health a
Autor:
Inna Chervoneva, Amy R. Peck, Yunguang Sun, Misung Yi, Sameer S. Udhane, John F. Langenheim, Melanie A. Girondo, Julie M. Jorns, Lubna N. Chaudhary, Sailaja Kamaraju, Carmen Bergom, Michael J. Flister, Jeffrey A. Hooke, Albert J. Kovatich, Craig D. Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Terry Hyslop, Marja T. Nevalainen, Richard G. Pestell, Serge Y. Fuchs, Edith P. Mitchell, Hallgeir Rui
Publikováno v:
JCO Precision Oncology.
PURPOSE T-cell–mediated cytotoxicity is suppressed when programmed cell death-1 (PD-1) is bound by PD-1 ligand-1 (PD-L1) or PD-L2. Although PD-1 inhibitors have been approved for triple-negative breast cancer, the lower response rates of 25%-30% in